Benefits of polyunsaturated fatty acid (PUFA) supplementation in therapy of children and teenagers with Asperger?s Syndrome

Benefits of PUFA supplementation in therapy of children and teenagers with Asperger?s Syndrome ? pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN20233876

Enrollment

Registered

2012-09-27

Start date

2011-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asperger's syndrome Mental and Behavioural Disorders Asperger's syndrome

Interventions

Post randomization, the patients will be receive polyunsaturated fatty acid (n=25) or placebo (n=25) capsules for 3 months. This will be followed by a switch over of the placebo group to PUFA and furt

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Asperger?s syndrome according to ICD-10 (normal IQ) 2. Age 6 ? 19 years

Exclusion criteria

Exclusion criteria: Patients meeting at least one of below mentioned criteria (in the past or currently) will be excluded from participation in the study: 1. Bipolar disease 2. Psychotic disorders 3. Immunological disorders 4. Administration of PUFA or other fat supplements (e.g. lecithin) during last 3 months 5. Body mass index (BMI) lower than 18 6. Convulsions in the history (excluding high temperature convulsions) 7. Administration of epileptic drugs currently or in the past 8. Administration of alcohol or narcotic drugs during the last 3 months 9. Blood hypertension 10. Hyper- or hypothyroidism 11. Diabetes or glucose intolerance 12. Hyperlipidemia 13. Clotting abnormalities 14. Other acute or chronic diseases currently or in the past

Design outcomes

Primary

Measure	Time frame
1. To evaluate the possible benefits of PUFA supplementation in patients with Asperger?s syndrome and autistic 'well functioning' children and teenagers with normal intelligence index and well-developed speaking abilities. 2. Changes in the core clinical symptoms pertaining to behavior and learning will be assessed by Conners Parent Rating Scales, psychiatric examination and questionnaire of symptoms, discussion with parents, based on ICD-10, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), Australian Scale for Asperger?s Syndrome of M.S. Garnett and A.J. Atwood, Asperger Syndrome Diagnostic Interview (ASDI) developed by the investigator.	—

Measure

Time frame

1. To evaluate the possible benefits of PUFA supplementation in patients with Asperger?s syndrome and autistic 'well functioning' children and teenagers with normal intelligence index and well-developed speaking abilities. 2. Changes in the core clinical symptoms pertaining to behavior and learning will be assessed by Conners Parent Rating Scales, psychiatric examination and questionnaire of symptoms, discussion with parents, based on ICD-10, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), Australian Scale for Asperger?s Syndrome of M.S. Garnett and A.J. Atwood, Asperger Syndrome Diagnostic Interview (ASDI) developed by the investigator.

—

Secondary

Measure	Time frame
To prepare initial indications to supplement subjects with Asperger?s syndrome and autistic 'well functioning' children and teenagers with PUFA, based on psychiatric and psychological evaluation, and blood tests.	—

Countries

Poland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026